



Review Article

Aptamers based targeted drug delivery system: A newer trend in cancer treatment therapy

Paramita Dey^{1*}, Anushmita Ghosh¹, Subhrajit Sarker¹

¹Bengal School of Technology, Sugandha, West Bengal, India



ARTICLE INFO

Article history:

Received 01-10-2023

Accepted 17-11-2023

Available online 01-02-2024

Keywords:

Cancer

Cancer treatment

Aptamer

SELEX

Target delivery

Conjugate

ABSTRACT

The investigation of targeted drug delivery systems as a way to improve therapeutic efficacy while minimizing adverse effects is a result of the development of novel cancer treatment strategies. This subject explores the exciting field of aptamer-based targeted drug delivery systems for the treatment of cancer. Short single-stranded DNA or RNA molecules called aptamers have a remarkable capacity to bind to particular target molecules with high specificity and affinity. Aptamers have drawn attention as excellent possibilities for creating targeted drug delivery systems by taking use of their special characteristic. The applications, choice, and modification of aptamers to precisely identify cancer-associated biomarkers, such as receptors overexpressed on cancer cells, are covered in detail in this topic. Additionally, it emphasizes various techniques for aptamer-drug conjugation optimization which ensure effective carrier delivery and regulated drug release inside the tumor microenvironment. It is investigated if aptamer-based systems have the ability to overcome problems such drug resistance, heterogeneity, and insufficient drug penetration within solid tumors.

In conclusion, this article illuminates how aptamer-based targeted drug delivery systems have transformed the world of cancer treatment. It advances knowledge of these systems and their potential to transform cancer treatment by providing insights into design principles, delivery systems, and therapeutic results.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Cancer is the most prevalent life-threatening disease that is characterised by uncontrolled growth and spread of abnormal cell. Metastasis is the stage where the cancer cells grows and lead to death. Cancer is caused by many external factors which includes chemicals, radiation, tobacco, and infectious organisms as well as some internal factors which includes hormones, immune conditions, inherited mutations and random mutations.¹ The abnormal cell growth occurs due to change in the DNA structure which are called as genes. A change in DNA can help the gene to grow unwanted cell growth. And other reason includes for the

abnormal cell growth is the environmental factors and genetic disorders. Most common cancers are caused due to mutation in somatic cells. Cancer is directed by two classes of genes which include oncogenes and tumour suppressor genes (TSGs) and each providing an important role in normal cells. In cancer, activating mutations of proto-oncogenes (mutated versions of normal cellular genes) can be caused uncontrolled cell division, which enhanced survival even after anti-cancer treatment and dissemination.² For this situation the treatment includes surgery, radiation, and immunotherapy medication.³

Cancer is still leading cause of death despite advances in major treatments for cancer such as surgery, radiotherapy, chemotherapy and immunotherapy.⁴⁻⁶ Though the first three treatments directly target the cancer cell but

* Corresponding author.

E-mail address: paramita.dey6@gmail.com (P. Dey).

immunotherapy attacks the tumor through host immune system.^{7,8} Although chemotherapy and radiotherapy are effective treatments, their side effects not only have a long-term negative impact on the patients' quality of life but also raise mortality rates and reduce the options for additional therapy.⁹

Cancer *chemotherapy* is a recognized treatment approach that can be used alone or in conjunction with surgery and radiation therapy to cure cancer.¹⁰ Chemotherapy is a successful method of treating cancer, but it faces significant challenges due to unfavourable side effects and the emergence of drug resistance that leads to multi-drug resistance (MDR).¹¹ The lack of selectivity for tumor cells over normal cells, which results in insufficient drug concentrations in tumors, systemic toxicity, and the emergence of drug-resistant tumor cells, limits the effectiveness of this approach.¹²

The goal of *radiotherapy* is to spare healthy tissues while sculpting the ideal isodose on the tumor volume. Patient recovery, organ preservation, and cost effectiveness are all three advantages. Proton and particle beam radiation, which is frequently used in conjunction with surgery and other medical interventions in a multidisciplinary and individualized approach to cancer treatment, has recently been added to these advancements.¹³ Radiation sensitivity in cells ranges widely, with cancer stem cells typically being radio resistant.¹⁴ Radiation therapy-related toxicities have gained attention due to the improved clinical results of cancer treatment. To further increase the radiation treatment's therapeutic ratio, radiation is also given in conjunction with molecular targeted therapy.^{15–19}

Cancer *immunotherapy* is a cutting-edge method of treating malignancies nowadays. Immunotherapy has been shown in numerous tests and clinical research to offer unmatched benefits over conventional anti-tumor therapy, which can extend progression-free survival (PFS) and overall survival (OS). Immunotherapy will always have an edge over other treatments since the immune system has the capability to remember and the ability to identify and eliminate tumor variations as they arise.²⁰ In contrast to traditional cancer therapies, immunotherapy not only eliminates primary tumors but also stops metastasis and recurrence. However, because immune cells are frequently not adequately supplied cancer antigens, current cancer immunotherapies offer modest therapeutic benefits. Solid tumors also circumvent anti-cancer immunity, unlike lymphoma, by developing an immune-suppressive tumor microenvironment (TME). Nanoparticles made of biomaterials are one strategy for bypassing these restrictions of cancer immunotherapy.²¹ Implementing existing and potential solutions, such as the development of more targeted cancer immunotherapies, personalized treatment with cancer immunotherapy drug combinations, cancer immunoprevention strategies, and

other significant innovations, will probably enable us to overcome current challenges.^{22–27}

Due to its sensitivity towards cancer cells while minimizing harm to off-target cells, *targeted therapy* has recently gained prominence. The goal of targeted therapy is to deliver medications to specific genes or proteins that are unique to cancer cells or the tissue milieu that supports the formation of cancer. These substances may be medications that prevent cancer cell proliferation, encourage cell cycle regulation, or trigger apoptosis or autophagy. In targeted therapy, monoclonal antibodies or orally administered, tiny medicines are used.^{11,28} Recent developments have produced integrated nanodevices for early cancer detection and screening, multifunctional nanoparticle probes for molecular and cellular imaging, and nanoparticle medicines for targeted therapy. These innovations have created exciting new possibilities for personalized oncology, in which cancer detection, diagnosis, and treatment are tailored to each patient's molecular profile, as well as predictive oncology, in which genetic and molecular data are used to forecast tumor onset, progression, and clinical outcome.²⁹ For instance, when doxorubicin, a routinely used anticancer medicine, is non-specifically absorbed by non-targeted tissues, such as those of the cardiovascular system, it can result in congestive heart failure and dilated cardiomyopathy. The dosage and methods of administration are directly inversely correlated with the severity of complications brought on by these antineoplastic.³⁰ These drugs must be administered specifically to targeted tumors at a low dose in order to eliminate these negative effects. For the treatment of cancer, several attempts have been undertaken to create targeted drug delivery systems.^{31,32} A new class of targeting-capable biomolecules, known as aptamers, developed with the introduction of the systemic evolution of ligands by exponential enrichment processes.^{33,34}

2. Aptamers

According to Ellington and Szostak, aptamers were discovered in 1990 and are a large group of randomly sequenced RNA molecules that are specifically attached to chemical dyes.³⁵ A single-stranded DNA or RNA structure called an aptamer fold into a special tertiary structure for interacting with particular targets; the complimentary forms of aptamers and targets enable binding. Aptamers have a number of advantages over other ligands, including small size, ease of synthesis, great chemical stability, full engineering, and minimal immunogenicity.³⁶ Aptamers are appealing for targeted therapy because of these qualities. A number of aptamers have been tested thus far and have shown significant potential in a variety of applications, including diagnostics, prognostics, and therapies for human virus and cancer diseases.³⁷ The advantages of aptamers are comparable to those of antibodies in that they can bind

to particular targets with a high affinity. Because of their great selectivity to targets, aptamers have slowly emerged as one of the research hotspots in the area of disease-targeted therapy. Because of their non-immunogenic traits, high specificity, and stability, aptamers are thought to be promising therapeutic agents. Aptamers can pair with the nano-carrier or directly interact with the medicines to decrease systemic toxicity.^{38–40} Aptamers are referred to as "chemical antibodies" due to their low cost and ease of modification.⁴¹ Aptamers, which are single-stranded DNA or RNA oligonucleotides that are very short and can imitate an antibody's antigen specificity, have been proven to have extremely high specificity for drug delivery in cancer chemotherapy.^{42–45} Additionally, they can easily be created or chemically developed to either tighten or loosen their affinity for a specific target molecule, like a cancer antigen. In this regard, SELEX (systemic evolution of ligands by exponential enrichment) has been created and utilized to evolve and select a specific DNA or RNA aptamer that has a desired affinity for an interest cancer antigen.⁴⁶ In this method, a variety of medicinal and sensing aptamers have been found.^{47,48}

2.1. Types of aptamers

RNA aptamers and DNA aptamers are the two main types of aptamers. The majority of research in the early stages of aptamer development was devoted to RNA aptamers. Because of their distinct tertiary structure and single-stranded nature, RNA aptamers may bind to targets more firmly and precisely. Drugs and other ligands can easily enter cells and be delivered to their targets because an RNA aptamer with a single strand structure is often smaller than a DNA aptamer. Numerous studies show that RNA aptamers are better able to bind to particular targets.^{49–51} There are some more aptamers includes protein aptamers, small molecule aptamers, nucleic acid aptamers, cell-specific aptamers, therapeutic aptamers.

2.2. Sources of aptamer (SELEX)

The first T4 DNA polymerase binding affinity was discovered by Tuerk and Gold, who arbitrarily selected two RNA sequences from an RNA library. The technique is known as Systematic Evolution of Ligands by Exponential Enrichment (SELEX).⁵² Since then, in vitro aptamer selection has been done frequently using the SELEX approach. The general SELEX procedure is as shown in Fig. 1.^{53–55} Traditional SELEX primarily consists of three procedures: Choosing ligand sequences that bind to the target; separating aptamers from non-aptamers using an affinity technique; and amplifying nodule-suitable bodies.

A realistic way to select aptamers against tiny compounds, proteins, bacteria, viruses, cell lines, and even complete cells is through the use of SELEX.⁵⁷ In

recent years, a number of screening techniques have been developed as a result of the rapid growth of SELEX, including Conventional SELEX and SELEX for complex targets, Affinity chromatography SELEX, SELEX for tissue slides, SELEX for magnetic beads, SELEX for capillary electrophoresis, SELEX for genomics, MSD-SELEX for monoclonal surface display, and Cell-SELEX. SELEX targets expressed on cell surfaces (TECS-SELEX), fluorescence-activated cell sorting (FACS-SELEX), and 3D cell sorting (Hybrid-SELEX), among others, have also been created using Cell-SELEX.

3. Applications of Aptamer

The local concentration and efficacy of cancer treatments have been improved by the use of aptamers tailored to cancer biomarkers. Due to its numerous advantages, which include stability for long-term storage, simplicity of synthesis and use, and minimal immunogenicity and resistance, aptamers have recently gained popularity as a tool for treating and identifying specific malignancies.⁵⁸ Trastuzumab and pertuzumab are presently used to treat breast tumors that express the human epidermal growth factor receptor 2 (HER2).^{59,60} Unfortunately, the major downside of this treatment is the development of resistance.⁶¹ Aptamer has been emphasized as a desirable substitute in regard to this.

3.1. Applications for diagnostics based on aptamers

Aptamers are showing increasing promise as a cancer diagnostic and imaging tool. Aptamer-nanoparticle (Apt-NP) conjugates are one of the most useful systems for cancer diagnostics, as is well known. These conjugates enable the detection of cancer cells in complicated bodily fluids like blood and serum. The nuclease activity of cancer cells is shielded by nanoparticles when aptamers are used to identify them with great sensitivity and selectivity (Figure 1). According to Borghei's research, AS 1411 aptamer nucleotides have been conjugated with gold nanoparticles (AuNP) and colorimetric analysis has been devised to more effectively detect MCF-7 breast cancer cells. Aptamers are trapped because of their affinity for the nucleolin receptors on cancer cells. The AS 1411 aptamer was taken out of the mixture because it adhered to breast cancer cells.⁶² AS1411, also referred to as an anti-nucleolin aptamer, is a stable, 26-base guanine-rich oligonucleotide that binds to the target nucleolin receptors that are overexpressed on cancer cells.^{63,64} Since normal cells lack or have less nucleolin receptors than cancer cells, nucleolin may be used as a tumor biomarker to distinguish between the two types of cells.⁶³ As a result, a particular interaction between AS1411 and nucleolin may someday make it possible to use therapeutic drugs to target cancer cells very precisely and successfully.^{65,66}





Figure 1: shows the general procedure of traditional SELEX and how it is used in breast cancer. The technique has been used extensively for in vitro aptamer selection. To identify tumor cells and treat breast cancer, aptamers are coupled with imaging labels or nanoparticles. To screen breast cancer aptamers, proteins-based SELEX and cells-based SELEX, two separate types of SELEX, are often used.⁵⁶

A number of biomarkers have also been found using aptamers, mainly because they can be chosen without being aware of their chemical identification beforehand. The biotinylated aptamer sgc8 was used to identify PTK7 in a variety of cancer cells. PTK7, a pseudokinase devoid of tyrosine kinase activity, requires further study. PTK7 was found to be expressed, albeit in various ways, in both many healthy cells and tumors thanks to aptamers. PTK7 expression is upregulated throughout the development of cancer, pointing to its potential value as a diagnostic or therapeutic marker.⁶⁷

Biomarkers can be created from the overexpression of surface proteins on cancer cells in order to detect some diseases early. In a study published in 2020, Raja Chinnappan et al. discovered that anti-VCAM-1 and anti-IL4R DNA aptamers were overexpressed on Vascular Cell Adhesive Molecule-1 in mice with the 4T1 tumor. They could serve as therapeutic indicators in addition to being diagnostic ones. The vitality and luciferase activity of 4T1-Luc2 cancer cells can be determined by measuring the absorbance and fluorescence of anti-VCAM-1 ssDNA or anti-IL4R RNA aptamers. The bioluminescence experiment and cell viability confirmed that these particular aptamers induced apoptosis in 4T1-Luc2 cells. To summarize, 4T1-Luc2 tumor-bearing mice were used to detect breast cancer by overexpressing the biomarkers anti-VCAM1 and anti-IL4R.⁶⁸

3.2. Therapy based on aptamers

Chemotherapy is still the most popular cancer treatment option as of right now. However, chemotherapy is always accompanied by a number of negative effects. Most medications kill both cancerous and healthy cells, thus they are not selective. For instance, trastuzumab and pertuzumab can be used to treat breast tumors that have HER2 positive.^{59,60} Unfortunately, resistance to this treatment is one of its biggest drawbacks.⁶¹ However, this restriction may be overcome and the efficacy and specificity of chemotherapeutic medicines may be enhanced by focusing on their distribution. Given this, aptamer has become a tempting alternative.



Therapeutic aptamers for targeted drug delivery. It is possible to divide aptamer-mediated active tumor targeted therapy into six groups and ten types, including aptamers as drugs, bi-specific aptamer systems, aptamer-small interfering RNA (siRNA) conjugates, aptamer-locked nucleic acid (LNA) conjugates, aptamer-anti-microRNAs (miRNAs) conjugates, aptamer-drug conjugates (ApDCs), aptamer-drug-nanoparticle conjugates, aptamer-peptide conjugates, aptamer-photodynamic treatment (PDT) agent conjugates, and aptamer-photothermal therapy (PTT) agent conjugates.

3.3. Therapeutic aptamers for targeted delivery of drugs

Aptamers are great choices for molecular probes since this special approach has high sensitivity and specificity to a particular target. Aptamers were shown by Sullenger et al. to be useful as therapeutic agents in 1990.⁶⁹ The FDA has authorized the use of pegaptanib (Macugen®), an aptamer that blocks VEGF165, to treat age-related macular degeneration.⁷⁰ Macugen is necessary for both permeability and angiogenesis. The use of various aptamers for particular diseases has been acknowledged since the US Food and Drug Administration approved the Macugen aptamer specific for vascular endothelial growth factor in 2004 for the treatment of age-related macular degeneration.⁷¹ For instance, the medication ARC1779 works to inhibit the purpura-causing activated von Willebrand factor.⁷²

Additionally, scientists are creating aptamers that specifically interact with cancer cells in order to treat the disease. Similar to this, aptamers can be created to cure cancer by altering the immune system and thus blocking cancer cell proliferation. The micro environment and tumor cells both express the platelet-derived growth factor receptor (PDGFR), which is significantly expressed in invasive TNBC. In 2020, Simona et al. successfully suppressed tumor growth and metastasis in mouse models of TNBC by giving them a very effective PDGFR aptamer. As a result, a novel treatment that combines PDGFR aptamer and anti-programmed cell death-ligand 1 monoclonal antibodies (mAbs) was studied in TNBC. The aptamer potentiates the anti-proliferative effects of anti-PD-L1 mAb on TNBC cells based on its cross-reactivity between humans and animals. Additionally, when attached to active human and mouse lymphocytes, the aptamer increases the cytotoxic activity of lymphocytes against tumor cells. The aptamer's major advantage is that it improves the efficiency of tumor development and lung metastases that are hindered by antibodies. The medication also inhibits the Akt and ERK1/2 signalling pathways, enhancing intratumoral CD8 + T cells and reducing FOXP3 + Tregs.⁷³

4. ApDCs, or aptamer-drug conjugates

Chemotherapy is one of the cancer therapies that is most frequently utilized in the general population. Toxicity of healthy tissues is a usual restriction in traditional chemotherapy, as are side effects that reduce the efficacy of the treatment. When drugs are exposed less, they are less likely to be absorbed into healthy tissues; as a result, we anticipate fewer adverse effects and more therapeutic efficacy. Using ApDCs, which selectively carry medications to damaged tissues and cells and ignore healthy cells, this objective can be accomplished.^{67,74}

The usage of certain ligands in tumour-targeted therapy has increased. Aptamers can interact with a variety of targets with great affinity, specificity, and selectivity, including proteins, small compounds, viruses, bacteria, and live cells.^{75,76} Due to the general stability and structural reversibility of aptamers, a multitude of ApDCs designs are possible. Similar to antibody-drug conjugates (ADCs), ApDCs contain three molecules: an aptamer, a linker, and a drug from the warhead. Most aptamers deliver therapeutic agents that alter the function of disease biomarkers in addition to serving as recognition ligands for disease locations.⁷⁷ The most crucial of the three characteristics of targeted drug delivery is the specificity of the target molecule and the ligand.⁷⁸

Due to its compactness, biocompatibility, biosafety, and editability, a DNA tetrahedron has recently been claimed to be a novel nanomedicine and a viable drug vector.^{79–81} The DNA tetrahedron can be altered or loaded with different materials, such as aptamers and anticancer drugs.^{82,83} As one example, the aptamer AS1411 has the targeting and anticancer capabilities of G-rich DNA oligonucleotides.⁸⁴ The nucleolin protein, which is primarily present on the surface of tumor cells, can bond with this protein due to its G-quadruplex structure.^{85–87} Nucleolin is thought to be dysregulated in cancer cells because it is overexpressed on their membranes, which stimulates cell proliferation. As a DNA-based delivery system, Zhan et al. modified the DNA tetrahedron (T-AS1411) with a DNA aptamer (AS1411) that could attach to nucleolin for its cancer cell selectivity.

Doxorubicin (Dox), an effective chemotherapeutic medication, has demonstrated considerable promise in the treatment of various cancer types. However, its usage in clinical studies was constrained by a serious cardiotoxin issue and drug resistance.⁸⁸

Paclitaxel (PTX), an active chemotherapeutic drug, can be used to decrease cancerous tumors in the breast, lung, and ovary. PTX interferes with microtubule processing, which inhibits cell division.^{89–92} Despite Paclitaxel's success in treating cancer in people, there are a number of drawbacks. It exhibits multiple drug resistance, is toxic, rapidly clears, is non-specific, is insoluble in water, and is not physiologically accessible.^{91–94}

5. Conclusion

Aptamer-based targeted drug administration provides an exciting and cutting-edge method in the realm of medication delivery and individualized healthcare. The capacity of aptamers to precisely bind to target molecules sets them apart from other drug delivery methods in a number of ways. They offer a high level of selectivity, decreasing side effects that are not intended and lowering the possibility of systemic toxicity.

Aptamers are adaptable instruments for precision drug administration because they may be easily changed to improve their stability and pharmacokinetic characteristics. Their prospective uses cover a wide spectrum of illnesses, such as cancer, infectious infections, and neurological problems.

We foresee the creation of more complex aptamer-based medication delivery systems that are adapted to each patient's unique requirements as this field of study develops. These devices could completely alter how we administer drugs, optimizing therapeutic results while reducing side effects.

It's vital to recognize that there are still obstacles to be solved, including the need to optimize aptamer characteristics, increase production scale, and deal with regulatory approval procedures. Despite this, the quick development of aptamer science and technology points to a promising future for aptamer-based targeted drug delivery as a useful addition to the toolkit of treatments available to healthcare professionals, providing hope for future years of more successful and individualized medical interventions.

6. Source of Funding

None.

7. Conflict of Interest

None.

References

- Mathur G, Nain S, Sharma PK. Cancer: An overview. *Acad J Cancer Res.* 2015;8(1):1–9.
- Nenclares P, Harrington KJ. The biology of cancer. *Medicine.* 2020;48(2):67–72.
- Patel A. Benign vs Malignant Tumours. *Medicine.* 2020;6(9):1488. doi:10.1001/jamaoncol.2020.2592.
- Kucharska W, Kawecka MN, Gromkowska M. Cardiotoxicity of oncological treatment in children. *Adv Clin Exp Med.* 2012;21(3):281–8.
- Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. *Cancer Treat Rev.* 2011;37(4):300–11.
- Leach JC, Wang A, Ye K, Jin S. A RNA-DNA hybrid aptamer for nanoparticle-based prostate tumour targeted drug delivery. *Int J Mol Sci.* 2016;17(380):10–11.
- Li Z, Song W, Rubinstein M, Liu D. Recent updates in cancer immunotherapy: A comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. *J Hematol Oncol.* 2018;11(1):142. doi:10.1186/s13045-018-0684-3.
- Li T, Yao F, An Y, Li X, Duan J, Yang X. Novel complex of PD-L1 Aptamer and holliday junction enhances antitumour efficacy in-vivo. *Molecules.* 1067;26(4):1–12.
- Jin S, Ye K. Targeted drug delivery for breast cancer treatment. *Recent Pat. Anticancer Drug Discov.* 2013;8(2):143–53.
- Wiemann MC, Calabresi P. Principles of Current Cancer Chemotherapy. *Compr Ther.* 1983;3:6839689.
- Padma V. An overview of targeted cancer therapy. *BioMed.* 2015;5(4):19. doi:10.7603/s40681-015-0019-4.
- Xu G, Mcleod HL. Strategies for enzyme/prodrug cancer therapy. *Clin Cancer Res.* 2001;7:3314–24.
- Thariat J, Hannoun-Levi JM, Myint S. Past, Present and future of radiotherapy for benefit of patients. *Nat Rev Clin Oncol.* 2013;10(1):52–60.
- Schaue D, McBride W. Opportunities and challenges of radiotherapy for treating cancer. *Nat Rev Clin Oncol.* 2015;12(9):527–40.
- Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. *Nat Rev Cancer.* 2011;11(4):239–53.
- Brown J. Therapeutic targets in radiotherapy. *Int J Radiat Oncol Biol Phys.* 2001;49(2):319–26.
- Tofilon PJ, Saxman S, Coleman C. Molecular targets for radiation therapy: Bringing preclinical data into clinical trials. *Clin Cancer Res.* 2003;9(1):3518–20.
- Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future direction. *Int J Med Sci.* 2012;9(3):193–9.
- Sullinan R, Alatise OI, Anderson BO, Audisio R, Autier P, Aggarwal A. Global cancer surgery: delivering safe, affordable and timely cancer surgery. *Lancet Oncol Commissions.* 2015;16:1193–224.
- Oiseth SJ, Aziz MS. Cancer immunotherapy: brief review of the history, possibilities and challenges ahead. *J Cancer Metastasis Treat.* 2017;3:250–61.
- Park W, Heo YJ, Han D. New opportunities for nanoparticles in cancer immunotherapy. *Biomater Res.* 2018;22:24. doi:10.1186/s40824-018-0133-y.
- Alatrash G, Jackher H, Steafford PD, Mittendorf EA. Cancer immunotherapies, their safety and toxicity. *Expert Opin Drug Saf.* 2013;12(5):631–45.
- Zugazaguita J, Guedes C, Ponce S. Current challenges in cancer treatment. *Clin Ther.* 2016;38(7):1551–66.
- Karlitepe A, Ozalp O, Avci C. New approaches for cancer immunotherapy. *Tumour Biol.* 2015;36(6):4075–8.
- Klener P, Klener P, Otahal P, Latckova L. Immunotherapy approaches in cancer treatment. *Curr Pharm Biotechnol.* 2011;16(9):771–81.
- Smit MA, Jaffee EM, Lutz BR. Cancer immunoprevention- the next frontier. *Cancer Press Res.* 2014;7(11):1072–80.
- Ventola CL. Cancer Immunotherapy Part 3: Challenges and Future Trends. *PT.* 2017;42(8):514–21.
- Gerber DE. Targeted therapies: a new generation of cancer treatments. *Am Fam Physician.* 2008;77(3):309–11.
- Wang MD, Shin DM, Simons JW. Wie Nanotechnology for targeted cancer therapy. *Expert Rev Anticancer Ther.* 2007;p. 833–7.
- Minotti G, Saponiero A, Licata S, Menna P, Calafiore AM, Teodoei G, et al. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. *Clin Cancer Res.* 2001;7(6):1511–5.
- Kirpotin DB, Dewmmond DC, Shao Y, Shalaley MR, Hong K, Neilson UB, et al. Antibody targeting of long-circulating lipidic nanoparticle does not increase tumour localization but does increase internationalization in animal models. *Cancer Res.* 2006;66(13):6732–40.
- Gu XG, Schmitt M, Hiasa A, Nagata Y, Ikeda H, Sasaki Y, et al. A novel hydrophobized polysaccharide / oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune response against HER2-inpressing murine sacromas. *Cancer Res.* 1998;58(15)::3385–9.
- Jayasena SD. Aptamers: An emerging class of molecules that rival antibodies in diagnosis. *Clin Chem.* 1999;45(9):1098–650.
- Gatto B, Cavalli M. From protein to nucleic acid-based drugs: The role of biotech in anti-VEGF therapy. *Anticancer agents Med Chem.* 2006;6(4):287–301.

35. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. *Nature*. 1990;346(6287):818–22.
36. Ma H, Liu MM, Fau-Ali J, Ali M, Fau-Mahmood MM, Mahmood L, et al. Nucleic acid aptamers in cancer research, diagnosis and therapy. *Chem Soc Rev*. 2015;44(5):1240–56.
37. Germer K, Leonard M, Zhang X. RNA aptamers and their therapeutic and diagnostics applications. *Int J Biochem Mol Biol*. 2013;4(1):27–40.
38. Tang Y, Liu H, Chen H, Chen Z, Liu Y, Jin L, et al. Advances in aptamer screening and drug delivery. *J Biomed Nanotechnol*. 2020;16(6):763–88.
39. Barzaman K, Kdrani J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S. Breast cancer: Biology biomarkers and treatments. *Int Immunopharmacol*. 2020;84:106535.
40. Wu X, Shaikh AB, Yu Y, Li Y, Ni S, Lu A, et al. Potential diagnostic and therapeutic applications of oligonucleotide aptamers in breast cancer and treatments. *Int J Mol Sci*. 2017;18(9):1851. doi:10.3390/ijms18091851.
41. Liu M, Yu X, Chen Z, Yang T, Yang D, Yang D, et al. Aptamer selection and applications for breast cancer diagnostics and therapy. *J Nanobiotechnol*. 2017;15(1):81. doi:10.1186/s12951-017-0311-4.
42. Famulok M. Oligonucleotide aptamers that recognize small molecules. *Curr Opin Struct Biol*. 1999;9(3):324–9.
43. Nimjee SM, Qusconi CP, Sullenger BA. An emerging class of therapeutics. *Annu Rev Med*. 2005;56:555–83.
44. Chu TC, Marks JW, Lavery LA, Faulkner S, Rosenblum MG, Ellington AD, et al. Aptamer: toxin conjugates that specifically target prostate tumour cells. *Cancer Res*. 2006;66(12):5989–92.
45. Farokhzad OC, Cheng J, Teply BA, Sherifi J, Kantoff JS, Richie PW, et al. Targeted nanoparticle aptamer bioconjugates for cancer chemotherapy in vivo. *Proc Natl Acad Sci*. 2006;203:6315–20.
46. Jeong S, Ttan SR, Lee VJ, Lee SW. Selection of RNA aptamers specific to active prostate specific antigen. *Biotechnol Lett*. 2010;32:379–85.
47. Keste AD, Pai S, Ellington A. Aptamers on therapeutics. *Nat Rev Drug Discov*. 2010;9:537–50.
48. Mckeague M, Derosa MC. Challenge and opportunities for small molecule aptamer development. *J Nucleic Acids*. 2012;748913:1–21. doi:10.1155/2012/748913.
49. Thiel KW, Giangrendo P. Intracellular delivery of RNA-based therapeutics using aptamers. *Ther Deliv*. 2010;1(6):849–61.
50. Guo P. The emerging field of RNA nanotechnology. *Nat Nanotechnol*. 2010;5(12):833–42.
51. Fan R, Tao X, Zhai X, Zhu Y, Li Y, Chen Y, et al. Application of aptamer drug delivery system in the therapy of breast cancer. *Biomed Pharmacother*. 2023;111:114–444.
52. Tuerk C, Gold L. Systemic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. *Science*. 1990;249(4968):505–11.
53. Gopinath S. Methods developed for SELEX. *Anal Bioanal Chem*. 2007;387:171–82.
54. Vant-Hull B, Gold L, Zichi DA. Theoretical principles of in vitro selection using combinatorial nucleic acid libraries. *Curr Pustoc Nucleic Acid Chem*. 2000;9:1–16. doi:10.1002/0471142700.nc0901s00.
55. Codrea V, Hayner M, Hall B, Jhaveri P, Ellington A. In vitro selection of RNA aptamers to a small molecule target. *Curr Protoc Nucleic Acid Chem*. 2010;5:1–23.
56. Darmostuk M, Rimpelva S, Gbelcova H, Runl T. Current approaches in SELEX: An update to aptamer selection technology. *Biotechnol Adv*. 2015;33(6):1141–61.
57. Kaur H. Recent developments in cell-SELEX technology for aptamers selection. *Biochim Biophys Acta Gen Subj*. 2018;1862(10):2323–9.
58. Chabner BA, Roberts TG. Timeline: Chemotherapy and the war on cancer. *Nat Rev Cancer*. 2005;5:65–72.
59. Minckwitz V, Procter G, Benjunes D, Azambuja D, Zerdavas E. Adjuvant Pertuzumab and Trastuzumab in early HER2- Positive Breast Cancer. *N Engl J Med*. 2017;377(2):122–31.
60. Swain SM, Baselga J, Kim SB, Semiglazov RJ, Compone V. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *N Engl J Med*. 2015;372(8):724–34.
61. Higgins MJ, Baseiga J. Targeted therapies for breast cancer. *J Clin Invest*. 2011;121:3797–803.
62. Borghei YS, Hosseini M, Dadmehr M, Hosseinkhani S, Ganjali MR, Sheikhejad R, et al. Visual detection of cancer cells by colorimetric aptasensor based on aggregation of gold nanoparticles induced by DNA hybridization. *Anal Chim Acta*. 2016;904:92–7. doi:10.1016/j.aca.2015.11.026.
63. Ireson CR, Kelland LR. Discovery and development of anticancer aptamers. *Mol Cancer Ther*. 2006;5(12):2957–62.
64. Li Q, Maier SH, Li P, Peterhansl J, Belka C, Mayerle J. Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma. *Radiat Oncol*. 2020;15:189.
65. Guo J, Gao X, Su L, Xia H, Gu G, Pang Z. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. *Biomaterials*. 2011;32(31):8010–20.
66. Soundararajan S, Chen W, Spicer EK, Luck C. Fernandes The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells *Cancer Res*. *Cancer Res*. 2008;68(7):2358–65.
67. Zhu G, Chen X. Aptamer-based targeted therapy *Adv Drug Deliv Rev*. 2018;134:65–78.
68. Chinnappan R, Faraj A, Rahman AM, Abu-Salah KM, Mouffouk F, Zourob Anti-VCAM-1 and Anti-IL4R α Aptamer-Conjugated Super Paramagnetic Iron Oxide Nanoparticles for Enhanced Breast Cancer Diagnosis and. *Ther Mol*. 2020;25(15):3437.
69. Sullenger BA, Ungers GGHF, Gilboa UGF. Gilboa Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. *Cell Cell*. 1990;63:601–9.
70. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M. GUYER Pegaptanib for neovascular age-related macular degeneration *N Engl J Med*. 2004;p. 2805–21.
71. Jo H. Ban Aptamer-nanoparticle complexes as powerful diagnostic and therapeutic tools *Exp Mol Med*. 2016;48(5):e–230.
72. Gilbert JC, Defeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers *Circulation*. 2007;116:2678–86.
73. Camorani S, Passariello M, Agnello L, Esposito S, Collina F, Cantile M. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer. *J Exp Clin Cancer Res*. 2020;15(7):39. doi:10.3390/cancers15072010.
74. Kroemer G, Senovilla L, Galluzzi L, André F. Zitvogel Natural and therapy-induced immunosurveillance in breast cancer *Nat Med*. 2015;21(10):1128–66.
75. Zhou J. Aptamers as targeted therapeutics: current potential and challenges *Nat Rev Drug Discov*. 2017;16(3):181–202.
76. Zhong Y, Zhao J, Li J, Liao X, Chen F. Advances of aptamers screened by Cell-SELEX in selection procedure, cancer diagnostics and therapeutics. *Anal Biochem*. 2020;598:113620.
77. Hu R, Zhang X, Zhao Z, Zhu G, Chen T, Fu T, et al. DNA nanoflowers for multiplexed cellular imaging and traceable targeted drug delivery. *Angew Chem Int Ed Engl*. 2014;53(23):5821–6.
78. Wan LY, Yuan WF, Ai WB, Ai YW, Wang JJ, Chu LY. An exploration of aptamer internalization mechanisms and their applications in drug delivery *Expert Opin Drug Deliv*. 2019;16(3):207–18.
79. Liang L, Li J, Li Q, Huang Q, Shi J, Yan H. Single-particle tracking and modulation of cell entry pathways of a tetrahedral DNA nanostructure in live cells. *Angew Chem Int Ed Engl*. 2014;53(30):7745–50.
80. Pei H, Lu N, Wen Y, Song S, Liu Y, Yan H. A DNA nanostructure-based biomolecular probe carrier platform for electrochemical biosensing. *Adv Mater*. 2010;22(42):4754–8.
81. Pei H, Zuo X, Zhu D, Huang Q, Fan Functional DNA nanostructures for theranostic applications *Acc Chem Res*. 2014;47(2):550–9.
82. Son J, Lee J, Tandon A, Kim B, Yoo S, Lee CW. Assembly of a tile-based multilayered DNA nanostructure. *Nanoscale*. 2015;7(15):6492–7.

83. Xia Z, Wang P, Liu X, Liu T, Yan Y, Yan J. Tumor-penetrating peptide-modified DNA tetrahedron for targeting drug delivery. *Biochemistry*. 2016;55(9):1326–57.
84. Malik MT, O’toole MG, Casson LK, Thomas SD, Bardi GT, Reyes-Reyes EM. AS1411-conjugated gold nanospheres and their potential for breast cancer therapy. *Oncotarget*. 2015;6:22270–22281.
85. Reyes-Reyes EM, Teng Y, Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. *Cancer Res*. 2010;70(21):8617–46.
86. Reyes EM, Šalipur FR, Shams M, Forsthoefel MK. Bates Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation. *Mol Oncol*. 2015;9(7):1392–405.
87. Dam DH, Lee JH, Sisco PN, Co DT, Zhang M, Wasielewski MR, et al. Direct observation of nanoparticle-cancer cell nucleus interactions. *ACS Nano*. 2012;6(4):3318–26.
88. Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. *J Pharm Pharmacol*. 2013;65:157–70.
89. Esfandyari-Manesh M, Mohammadi A, Atyabi F, Nabavi SM, Ebrahimi SM, Shahmoradi E, et al. Specific targeting delivery to MUC1 overexpressing tumors by albumin-chitosan nanoparticles conjugated to DNA aptamer. *Int J Pharm*. 2016;515:607–15.
90. Ndungu JM, Lu YJ, Zhu S, Yang C, Wang X, Chen G. Targeted delivery of paclitaxel to tumor cells: synthesis and in vitro evaluation. *J Med Chem*. 2010;53(8):3127–32.
91. Shiao YS, Chiu HH, Wu PH, Huang YF. Aptamer-functionalized gold nanoparticles as photoresponsive nanoplatform for co-drug delivery. *ACS Appl Mater Interfaces*. 2014;6:21832–41.
92. Taghdisi SM, Danesh NM, Lavaee P, Emrani AS, Hassanabad KY, Ramezani M. Double targeting, controlled release and reversible delivery of daunorubicin to cancer cells by polyvalent aptamers-modified gold nanoparticles. *Mater Sci Eng C Mater Biol Appl*. 2016;61:753–61. doi:10.1016/j.msec.2016.01.009.
93. Jahangirian H, Kalantari K, Izadiyan Z, Moghaddam RR, Shameli K, Webster TJ. A review of small molecules and drug delivery applications using gold and iron nanoparticles. *Int J Nanomed*. 2019;14:1633–57.
94. Elgqvist J. Elgqvist Nanoparticles as theranostic vehicles in experimental and clinical applications-focus on prostate and breast cancer. *Int J Mol Sci*. 2017;18(5):1102.

Author biography

Paramita Dey, Professor

Anushmita Ghosh, Student

Subhrajit Sarker, Student

Cite this article: Dey P, Ghosh A, Sarker S. Aptamers based targeted drug delivery system: A newer trend in cancer treatment therapy. *J Pharm Biol Sci* 2023;11(2):97-104.